A study to desribe usage of antifungal drugs in Selected Clinical Care Settings of a Tertiary Care Teaching Hospital
Not Applicable
- Conditions
- Health Condition 1: null- ICU patients
- Registration Number
- CTRI/2018/05/013733
- Lead Sponsor
- KEM Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients admitted in either MICU, PICU or in Hematology ward and receiving antifungal drugs as a part of his/her treatment.
2. Patients or LAR willing to give informed consent
Exclusion Criteria
1. Re-consent refusal from patient, after regaining consciousness when admitted in unconscious state
2. Patients receiving prophylactic antifungal therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a. extent of use of antifungal drugs Prescribed Daily Doses (PDDs) & Duration Of Therapy (DOTs) <br/ ><br>b. Appropriateness of antifungal useTimepoint: a. extent of use of antifungal drugs Prescribed Daily Doses (PDDs) & Duration Of Therapy (DOTs) <br/ ><br>b. Appropriateness of antifungal use
- Secondary Outcome Measures
Name Time Method a. Total number of adverse events occurring in patients receiving antifungal drugs <br/ ><br>d. Percentage of adverse reactions causally related to AFAs: according to WHO-UMC or Naranjo algorithm <br/ ><br>c. Severity of ADRs as per modified Hartwig-Siegel scale <br/ ><br>d. Percentage of ADRs which are preventable, according to Schumock and Thornton scale <br/ ><br>Timepoint: first visit: Day 0 <br/ ><br>subsequent visits: daily till participant is discharged <br/ ><br>